Share
Information on reimbursement
-
08 March 2012
Review concluded regarding general reimbursement for Valsartan/Hydrochlorothiazide "Actavis"
We have completed our review of an application for general reimbursement for Valsartan/Hydrochlorothiazide "Actavis". The product is neither eligible for general nor general conditional reimbursement.
-
06 March 2012
Comments received on the reassessment of reimbursement status of antidiabetic medicines (ATC group A10)
The Danish National Board of Health has received a number of comments from stakeholders about the Reimbursement Committee's discussion of the reimbursement status of antidiabetic medicines (ATC group A10).
-
21 February 2012 | Updated 22 February 2012
Decision on general conditional reimbursement for alendronate-containing medicines
In cooperation with the Reimbursement Committee, we have decided to grant alendronate-containing medicines general conditional reimbursement from 5 March 2012. Reimbursement is conditional as it is reserved for patients with low-energy hip fractures. For any other patients who are treated with alendronate, the doctor must apply for single reimbursement, and the guiding criteria for single reimbursement remain unchanged for these patients. Alendronate is used for the treatment of osteoporosis (brittle bones).
-
21 February 2012 | Updated 22 February 2012
Changed criteria for single reimbursement for osteoporosis medicines other than alendronate
As of 5 March 2012, it will only be possible to obtain a single reimbursement grant for the other medicines used in osteoporosis treatment for patients that cannot use alendronate. The criteria for single reimbursement are changed because of the large price gaps between the different medicines, where the reimbursement price of alendronate is by far the lowest.
-
02 February 2012
Applications for general reimbursement in 2011
In 2011, we reviewed 21 applications for general reimbursement for 20 different medicinal products. 15 of the applications ended with the granting of general reimbursement or general conditional reimbursement, and the remaining six applications were refused.
-
25 January 2012
Review concluded regarding general reimbursement for Xarelto®
The Danish Medicines Agency has completed its review of an application for general reimbursement for two new strengths of Xarelto®. The product maintains general reimbursement.
-
20 January 2012
Review concluded regarding general reimbursement for Zomig Nasal®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Zomig Nasal®. The product has been granted general reimbursement.
-
17 January 2012
Decision on general reimbursement for Yellox®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Yellox®. The product has been granted general reimbursement.
-
16 January 2012
Review concluded regarding general reimbursement for Multaq®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Multaq®. The product is neither eligible for general nor general conditional reimbursement.
-
13 January 2012
Reassessment of reimbursement status of antidiabetic medicines (ATC group A10)
On 22 December 2009, the Danish Medicines Agency announced that we would begin our reassessment of the reimbursement status of a number of groups of medicines, including antidiabetics (ATC group A10). Within a few months, the Reimbursement Committee will begin to discuss the reimbursement status of antidiabetics.
-
05 January 2012
All changes completed regarding abolition of increased co-payment for fertility medicine
As part of the abolition of the increased co-payment for fertility medicine on 1 January 2012, the Danish Parliament adopted interim provisions to ensure that no one was financially worse off than they would have been according to the rules in force in 2011.
-
05 January 2012
Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of strong painkillers (opioids)
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N02A, opioids, as well as certain medicines in ATC groups N07BC and R05DA.
-
04 January 2012
Abolition of increased co-payment for fertility medicine as of 1 January 2012
On 21 December 2011, the Danish Parliament adopted an amendment of the Danish Health Act with effect from 1 January 2012. It abolishes the increased co-payment for fertility medicine that was introduced on 1 January 2011. Please find a link to the Danish bill in the box to the right. There are a number of implications for users of fertility medicine.
-
03 January 2012
Review concluded regarding general reimbursement for Sativex®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Sativex®. The product is neither eligible for general nor general conditional reimbursement.
-
12 December 2011
Changed practice for single reimbursement for hyaluronic acid
In collaboration with the Reimbursement Committee, the Danish Medicines Agency has decided to change the practice for granting single reimbursement for hyaluronic acid. As of 15 January 2012, we will only grant single reimbursement for hyaluronic acid in exceptional circumstances and not, as we have done thus far, to all patients with osteoarthritis of the knee. In the period up until 15 January 2012, we will introduce a time limit on single reimbursement grants for hyaluronic acid to patients with knee osteoarthritis. In Denmark, hyaluronic acid is available as the two medicines Hyalgan® and Artz®, and they are used for patients with knee osteoarthritis for alleviating pain and improving the function of the knee joint.
-
15 November 2011
Review concluded regarding general reimbursement for Adepend®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Adepend®. The product is neither eligible for general nor general conditional reimbursement. Adepend® is used as part of treatment of alcoholism. When we compare treatment with Adepend® with treatment with Antabuse, we assess that the price of the medicine is not reasonable relative to its therapeutic value.
-
11 November 2011
Review concluded regarding general reimbursement for Xiapex®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Xiapex®. The product is neither eligible for general nor general conditional reimbursement. Xiapex® is indicated for the treatment of Dupuytren's contracture.
-
04 November 2011
Comments received on the reassessment of reimbursement status of strong analgesics (opioids)
The Danish Medicines Agency has received a number of comments for the Reimbursement Committee's discussion of reimbursement status of strong analgesics (opioids). These comments were presented to the Reimbursement Committee at its meeting on 27 September 2011. The Reimbursement Committee is currently processing a recommendation.
-
01 November 2011
Decision on general reimbursement for Adenuric®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Adenuric®. The product is neither eligible for general nor general conditional reimbursement. Adenuric® is used for treatment of chronic hyperuricaemia (primarily gout).
-
21 October 2011
Decision on general reimbursement for Cholestagel®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Cholestagel®. The product is neither eligible for general nor general conditional reimbursement. Cholestagel® is used for treatment of elevated blood cholesterol levels.
